Interestingly, both anti-CD19 CAR-T cell studies noted that dose fractionation reduced the toxicity of CAR-T cells whereas the anti-BCMA CAR-T cell study reported that CRS severity was similar between single dose and fractionated dose groups. This evidence concerns the gene CD19 and congenital rubella syndrome.